Indolent lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~17.7 mo | — | ~1 | — | 4 |
Observation Partial | — | — | — | ~25.4 mo | — | — | — | 8 |
3 of 3 regimens shown